Timolumab

• CAT Number: I042399
• CAS Number: 1073538-99-4
• Purity: ≥95%

Timolumab (Cat No.: I042399) is a human monoclonal antibody that targets programmed death-ligand 1 (PD-L1), a key immune checkpoint molecule involved in tumor immune evasion. By blocking the PD-1/PD-L1 interaction, Timolumab restores T-cell activity and enhances anti-tumor immune responses. It is being explored as an immunotherapeutic agent in the treatment of various cancers, including non-small cell lung cancer and melanoma. Timolumab is valuable for investigating immune checkpoint blockade strategies and improving outcomes in cancer immunotherapy, especially in combination with other immunomodulatory agents.

Reference

[1]. Ahmad H Ali, et al. Novel treatments in primary sclerosing cholangitis. Clin Liver Dis (Hoboken). 2016 Nov 30;8(5):132-135.
[Content Brief]

[2]. Takayuki Inoue, et al. Synthesis and SAR study of new thiazole derivatives as vascular adhesion protein-1 (VAP-1) inhibitors for the treatment of diabetic macular edema. Bioorg Med Chem. 2013 Mar 1;21(5):1219-33.
[Content Brief]

[3]. Anu Autio, et al. Preclinical evaluation of a radioiodinated fully human antibody for in vivo imaging of vascular adhesion protein-1-positive vasculature in inflammation. J Nucl Med. 2013 Aug;54(8):1315-9.
[Content Brief]